| Medical and Health Sciences | Lifetime | 316 | US 175 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 97 | US 39 | 99.98 |
| Biological Sciences | 2021-2025 | 738 | US 169 | 99.22 |
| Hematology | Lifetime | 12 | US 10 | 99.94 |
| Molecular Biology | Lifetime | 373 | US 235 | 99.83 |
| Oncology | Lifetime | 228 | US 126 | 99.63 |
| Medical Genetics | Lifetime | 217 | US 111 | 98.38 |
| Hematology | 2021-2025 | 5 | US 4 | 99.93 |
| Molecular Biology | 2021-2025 | 103 | US 23 | 99.59 |
| Oncology | 2021-2025 | 74 | US 31 | 99.57 |
| Medical Genetics | 2021-2025 | 111 | US 44 | 96.10 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 710 | US 244 | 83.57 |
| Cancer Treatment and Pharmacology | Lifetime | 13 | US 8 | 99.92 |
| Peptidase Inhibition and Analysis | Lifetime | 10 | US 6 | 99.92 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 7 | US 5 | 99.84 |
| Multiple Myeloma Research and Treatments | Lifetime | 10 | US 7 | 99.93 |
| Protein Degradation and Inhibitors | Lifetime | 8 | US 5 | 99.90 |
| Cancer Mechanisms and Therapy | Lifetime | 13 | US 7 | 99.64 |
| Ubiquitin and proteasome pathways | Lifetime | 57 | US 32 | 99.60 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 87 | US 57 | 99.68 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 30 | US 17 | 99.63 |
| Neuroendocrine Tumor Research Advances | Lifetime | 255 | US 110 | 98.95 |
| Cancer therapeutics and mechanisms | Lifetime | 283 | US 168 | 98.44 |
| Histone Deacetylase Inhibitors Research | Lifetime | 185 | US 114 | 98.08 |
| CAR-T cell therapy research | Lifetime | 480 | US 288 | 98.61 |
| Platelet Disorders and Treatments | Lifetime | 350 | US 138 | 97.94 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 369 | US 188 | 98.25 |
| Chemokine receptors and signaling | Lifetime | 163 | US 75 | 97.29 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 283 | US 172 | 97.65 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 484 | US 251 | 98.12 |
| Hematological disorders and diagnostics | Lifetime | 361 | US 171 | 95.09 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 275 | US 69 | 92.18 |
| Blood disorders and treatments | Lifetime | 780 | US 309 | 92.69 |
| Dermatological and Skeletal Disorders | Lifetime | 842 | US 286 | 87.08 |
| Biological Research and Disease Studies | Lifetime | 109 | US 25 | 65.96 |
| Protein Degradation and Inhibitors | 2021-2025 | 4 | US 1 | 99.88 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 6 | US 2 | 99.93 |
| Peptidase Inhibition and Analysis | 2021-2025 | 6 | US 1 | 99.78 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 30 | US 11 | 99.08 |
| Cancer Treatment and Pharmacology | 2021-2025 | 16 | US 7 | 99.69 |
| Ubiquitin and proteasome pathways | 2021-2025 | 24 | US 12 | 98.26 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 48 | US 26 | 99.31 |
| CAR-T cell therapy research | 2021-2025 | 86 | US 50 | 99.40 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 17 | US 7 | 99.18 |
| Cancer Mechanisms and Therapy | 2021-2025 | 30 | US 5 | 97.32 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 103 | US 60 | 97.33 |
| Cancer therapeutics and mechanisms | 2021-2025 | 62 | US 24 | 94.69 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 148 | US 80 | 97.22 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 171 | US 70 | 91.21 |
| HIV/AIDS drug development and treatment | 2021-2025 | 356 | US 120 | 90.67 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 350 | US 114 | 87.06 |
| Hematological disorders and diagnostics | 2021-2025 | 144 | US 52 | 80.88 |
| Chemokine receptors and signaling | 2021-2025 | 141 | US 26 | 80.92 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 936 | US 206 | 54.34 |
